

# *The* PANCREAS

AN INTEGRATED TEXTBOOK OF BASIC SCIENCE,  
MEDICINE, AND SURGERY

EDITED BY HANS G. BEGER, MARKUS W. BÜCHLER, RALPH H. HRUBAN,  
JULIA MAYERLE, JOHN P. NEOPTOLEMOS, TOORU SHIMOSEGAWA,  
ANDREW L. WARSHAW, DAVID C. WHITCOMB, and YUPEI ZHAO



FOURTH EDITION



WILEY Blackwell



# The Pancreas



# The Pancreas

An Integrated Textbook of Basic Science, Medicine, and Surgery

**Fourth Edition**

*Edited by*

**Hans G. Beger, MD, FACS (Hon.), JSS (Hon.), CSS (Hon.)**

*Founding Editor, Professor Emeritus of Surgery, University of Ulm, Ulm, Germany.*

**Markus W. Büchler, MD FACS (Hon.), FRCS (Hon.), FASA (Hon.)**

*Professor of Surgery, University of Heidelberg, Heidelberg, Germany.*

**Ralph H. Hruban, MD FACS (Hon.), FRCS (Hon.), FASA (Hon.)**

*Baxley Professor and Director, Department of Pathology, and Director of the Sol Goldman Pancreatic Research Center, Johns Hopkins University School of Medicine, Baltimore, USA.*

**Julia Mayerle, MD**

*Professor of Internal Medicine, Gastroenterology and Hepatology, Chair Department of Medicine II, LMU Klinikum, Ludwig-Maximilians-University, Munich, Germany.*

**John P. Neoptolemos, MA, MB, BCHIR, MD FRCS, FMEDSCI, MAE**

*Professor of Surgery, Department of Surgery, University of Heidelberg, Heidelberg, Germany.*

**Tooru Shimosegawa, MD, PhD**

*Professor Emeritus Department of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.*

**Andrew L. Warshaw, MD, FACS, FRCSEd (Hon.)**

*W. Gerald Austen Distinguished Professor of Surgery, Harvard Medical School, and Surgeon-in-Chief Emeritus, Massachusetts General Hospital, Boston, USA.*

**David C. Whitcomb, MD, PhD**

*Professor of Medicine, Cell Biology & Physiology, Human Genetics, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh and UPMC, Pennsylvania, USA.*

**Yupei Zhao, MD, FICS (Hon.), FACS (Hon.), FRCS (Engl) (Hon.), FCSHK (Hon.)**

*Professor of Surgery, Department of General Surgery, Peking Union Medical College Hospital, Beijing, P.R. China.*

*Coordinating Editor*

**Christiane Groß**

*German Foundation for the Fight Against Pancreatic Cancer, c/o University of Ulm, Ulm, Germany*

**WILEY** Blackwell

This edition first published 2023  
© 2023 John Wiley & Sons Ltd

*John Wiley & Sons Ltd* (1e 1998, 2e 2008, 3e 2018)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Hans G. Beger, Markus W. Büchler, Ralph H. Hruban, Julia Mayerle, John P. Neoptolemos, Tooru Shimosegawa, Andrew L. Warshaw, David C. Whitcomb, and Yupei Zhao to be identified as the editorial material in this work has been asserted in accordance with law.

#### *Registered Offices*

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at [www.wiley.com](http://www.wiley.com).

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product or vendor mentioned in this book.

#### *Limit of Liability/Disclaimer of Warranty*

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

#### *Library of Congress Cataloging-in-Publication Data*

Names: Beger, H. G. (Hans G.), editor.

Title: The pancreas : an integrated textbook of basic science, medicine, and surgery / edited by Hans G. Beger, Markus W. Büchler, Ralph H. Hruban, Julia Mayerle, John P. Neoptolemos, Tooru Shimosegawa, Andrew L. Warshaw, David C. Whitcomb, Yupei Zhao, Christiane Gross.

Other titles: Pancreas (Beger)

Description: Fourth edition. | Hoboken, NJ : Wiley, 2023. | Includes bibliographical references and index.

Identifiers: LCCN 2022047652 (print) | LCCN 2022047653 (ebook) | ISBN 9781119875970 (cloth) | ISBN 9781119875987 (adobe pdf) | ISBN 9781119875994 (epub)

Subjects: MESH: Pancreatic Diseases—physiopathology | Pancreatic Diseases—therapy | Pancreatectomy—methods | Pancreas—physiology

Classification: LCC RC857 (print) | LCC RC857 (ebook) | NLM WI 803 | DDC 616.3/7—dc23/eng/20221209

LC record available at <https://lccn.loc.gov/2022047652>

LC ebook record available at <https://lccn.loc.gov/2022047653>

Cover Design: Wiley

Cover Image: Courtesy of Carolyn Hruban

Set in 10/12pt WarnockPro by Straive, Pondicherry, India

## Preface

The fourth edition of *The Pancreas* presents the most comprehensive and latest knowledge about the genetic and molecular biological basis of embryology, anatomy, physiology, pathophysiology, and pathology for all disorders of the pancreas. Compared to the first edition, published in 1998, the fourth edition contains three newly addressed diseases of the pancreas: autoimmune pancreatitis, benign and premalignant cystic neoplasms, and neuroendocrine tumors. The understanding of the functions and dysfunctions of the exocrine and endocrine pancreas is derived from increasingly profound molecular biological data on the actions of compounds in subcellular compartments and intracellular transcription pathways. In the respective chapters, the presentation of the inflammatory (acute or chronic) and oncological diseases (benign, premalignant, or advanced cancer) is based on molecular biological understanding of pathomorphological processes and clinical phenomena. In clinical pancreatology, new and improved technical devices enable the gastroenterologist and the gastrointestinal surgeon to identify lesions by high-resolution imaging techniques, imaging of metabolic processes, and intrapancreatic ductal morphologic processes. The molecular profiling of pancreatic ductal adenocarcinoma has provided a deeper understanding of the genomic alterations that drive pancreatic ductal adenocarcinoma, including driver genes, actionable mutations, copy number alterations, patterns of genomic aberrations, structural variations, and mutational signatures. These findings have transformed our biological genomic understanding, but are still of limited clinical utility. Significant progress has been made in understanding the molecular pathogenesis of pancreatic cancer and identification of various molecular subtypes. However, this improved understanding has unfortunately not yet led to relevant progress for the patient's cure, although survival gain after radical cancer resection in addition with neoadjuvant chemotherapy is significant for selected groups of patients.

The synergistic interaction of basic scientists, pathologists, gastroenterologists, and gastrointestinal tract

surgeons in the field of investigative and clinical pancreatology has led to a better understanding of pancreatic diseases through combining the knowledge of each to achieve the best management. Most importantly, the decision-making for patients with an option to be successfully treated for pancreatic disease is increasingly based on high-evidence data from clinical trials on treatment. New technical devices—endoscopic visualization of cellular abnormalities, laparoscopic minimally invasive surgical approaches, and robotic surgery—have led to significant clinical improvement. The establishment of local, parenchyma-sparing surgical approaches for the increasing number of benign tumors, cystic neoplasms, and neuroendocrine tumors have significantly improved the patient's outcome compared to classical pancreatic resections.

The goal of this fourth edition is to provide the clinician with the most current evidence-based synthesis of understanding of pancreatic diseases, functional assessment, diagnostic and technical devices, treatment options, and outcome results. All chapters are written by leading international experts on the topic. A major part of this edition has been contributed by international basic scientists, who provide an understanding of the molecular basis of pancreatic functions and dysfunctions. The editors acknowledge and are deeply indebted to all authors who have contributed to this edition. Their diligent efforts have provided state-of-the-art knowledge, particularly in regard to decision-making based on clinical evidence.

*Hans G. Beger, Ulm*  
*Markus W. Büchler, Heidelberg*  
*Ralph H. Hruban, Baltimore*  
*Julia Mayerle, München*  
*John P. Neoptolemos, Heidelberg*  
*Tooru Shimosegawa, Sendai*  
*Andrew L. Warshaw, Boston*  
*David C. Whitcomb, Pittsburgh*  
*Yupei Zhao, Beijing*

## Contents

About the Companion Website *xvii*

### Section 1 Anatomy of the Pancreas 1

- 1 Development of the Pancreas and Related Structures 3  
*Brian Lewis and Junhao Mao*
- 2 Anatomy, Histology, and Fine Structure of the Pancreas 9  
*Daniel S. Longnecker and Elizabeth D. Thompson*
- 3 Congenital and Inherited Anomalies of the Pancreas 23  
*Heiko Witt and Martin Zenker*

### Section 2 Physiology and Pathophysiology of Pancreatic Functions 33

- 4 Physiology of Acinar Cell Secretion 35  
*Ole H. Petersen*
- 5 Physiology of Duct Cell Secretion 48  
*Wei-Yin Lin, Paramita Sarkar, and Shmuel Muallem*
- 6 Physiology and Pathophysiology of Function of Sphincter of Oddi 56  
*Savio George Barreto and James Toouli*
- 7 Neurohormonal and Hormonal Control of Pancreatic Secretion 65  
*Chung Owyang and Matthew J. DiMagno*
- 8 Regulation of Pancreatic Protein Synthesis and Growth 75  
*Maria Dolors Sans and John A. Williams*
- 9 Fibrogenesis in the Pancreas: The Role of Pancreatic Stellate Cells 86  
*Minoti V. Apte, Romano C. Pirola, and Jeremy S. Wilson*
- 10 Pancreatic Endocrine–Exocrine Relationship 98  
*Kenichiro Furuyama and Yoshiya Kawaguchi*



- Section 3 Acute Pancreatitis 105**
- 11 Epidemiology and Etiology of Alcohol-Induced Pancreatitis 107**  
*Jeremy S. Wilson, Romano C. Pirola, and Minoti V. Apte*
- 12 Epidemiology and Etiology of Biliary Acute Pancreatitis 119**  
*Ippei Ikoma, Ko Tomishima, and Hiroyuki Isayama*
- 13 Genetic Factors in Acute Pancreatitis 128**  
*Mitchell L. Ramsey and Georgios I. Papachristou*
- 14 The Role of the Intestine and Mesenteric Lymph in the Development of Organ Dysfunction in Severe Acute Pancreatitis 138**  
*Alistair B.J. Escott, Anthony R.J. Phillips, and John A. Windsor*
- 15 The Role of Neurogenic Inflammation in Pancreatitis 146**  
*Metrah Mohammad Nader and Jami L. Saloman*
- 16 Molecular, Biochemical, and Metabolic Abnormalities of Acute Pancreatitis 155**  
*Ujjwal M. Mahajan, F. Ulrich Weiss, Markus M. Lerch, and Julia Mayerle*
- 17 Histopathology of Acute Pancreatitis 164**  
*Günter Klöppel*
- 18 Severity Classification of Acute Pancreatitis 170**  
*John A. Windsor*
- 19 Clinical Assessment and Biochemical Markers to Objectify Severity and Prognosis 176**  
*Bettina M. Rau and Claus Schäfer*
- 20 Acute Pancreatitis Associated with Congenital Anomalies 185**  
*Charlotte S. Austin, Christopher R. Schlieve, Andrew L. Warshaw, and Tracy C. Grikscheit*
- 21 Acute Pancreatitis in Children 191**  
*Mark E. Lowe and Véronique D. Morinville*
- 22 Acute Pancreatitis Associated with Metabolic, Infections and Drug-Related Diseases 199**  
*Ali A. Aghdassi, Mats L. Wiese, Quang Trung Tran, and Markus M. Lerch*
- 23 Radiologic Diagnosis and Staging of Severe Acute Pancreatitis 208**  
*Yoshihisa Tsuji*
- 24 Conservative Therapy of Acute Pancreatitis: Volume Substitution and Enteral and Parenteral Nutrition 222**  
*Steven M. Hadley, Jr. and Timothy B. Gardner*
- 25 ICU Treatment of Severe Acute Pancreatitis 230**  
*Scott R. Gunn and David C. Whitcomb*
- 26 Clinical Course and Medical Treatment of Acute Pancreatitis—Use of Antibiotics in Severe Acute Pancreatitis: Indications and Limitations 238**  
*Rainer Isenmann and Mathias Wittau*

- 27 Indications for Interventional and Surgical Treatment of Necrotizing Pancreatitis 244**  
*Lily V. Saadat and Thomas E. Clancy*
- 28 Management of Infected Necrosis: Step-Up Approach 254**  
*Hester C. Timmerhuis, Marc G. Besselink, and Hjalmar C. van Santvoort*
- 29 Management of Infected Pancreatic Necroses: An Endoscopic Approach 260**  
*Todd H. Baron*
- 30 Minimally Invasive Debridement and Lavage of Necrotizing Pancreatitis 266**  
*Kulbir Mann and Michael G.T. Raraty*
- 31 Open Surgical Debridement of Necrotizing Pancreatitis: Late Postoperative Morbidity and Outcome 271**  
*Dongya Huang, Zipeng Lu, and Yi Miao*
- 32 Endoscopic Treatment of Acute Biliary Pancreatitis 278**  
*Ichiro Yasuda, Tsuyoshi Mukai, and Toru Ito*
- 33 Strategies for the Treatment of Pancreatic Pseudocysts and Walled-Off Necrosis After Acute Pancreatitis: Interventional Endoscopic Approaches 284**  
*Georg Beyer and Julia Mayerle*
- 34 Pseudocysts and Walled-Off Necrosis After Acute Pancreatitis: Surgical Approach 288**  
*Naohiro Sata, Masaru Koizumi, and Alan Kawarai Lefor*
- 35 Management of Fluid Collection in Acute Pancreatitis 294**  
*Georg Beyer, Simon Sirtl, Christoph Ammer-Herrmenau, and Albrecht Neesse*
- 36 Management of Pancreatic Fistula in Acute Pancreatitis 300**  
*Marta Sandini, Thilo Hackert, and Markus W. Büchler*
- 37 Long-Term Outcome After Acute Pancreatitis 306**  
*Christin Tjaden and Thilo Hackert*
- Section 4 Chronic Pancreatitis 315**
- 38 Definition and Classification of Chronic Pancreatitis 317**  
*David C. Whitcomb*
- 39 Molecular Understanding of Chronic Pancreatitis 326**  
*Bomi Lee, Monique T. Barakat, and Sohail Z. Husain*
- 40 Natural History of Recurrent Acute and Chronic Pancreatitis 334**  
*Rohit Das, Jorge D. Machicado, and Dhiraj Yadav*
- 41 Pediatric Recurrent Acute and Chronic Pancreatitis: Role of Pancreas Divisum 344**  
*Jiri Snajdauf, Michal Rygl, Barbora Kucerova, and Natalia Newland*
- 42 Clinical and Laboratory Diagnosis of Chronic Pancreatitis 349**  
*Georg Beyer, Markus M. Lerch, and Julia Mayerle*

- 43 Abdominal Imaging for the Diagnosis of Chronic Pancreatitis** 357  
*Atsushi Irisawa and Akira Yamamiya*
- 44 Endoscopic Ultrasound for Diagnosis of Chronic Pancreatitis Versus Pancreatic Cancer** 366  
*J. Enrique Domínguez-Muñoz, Julio Iglesias-García, José Lariño-Noia, and Daniel de la Iglesia-García*
- 45 Hereditary Pancreatitis and Complex Genetic Causes** 375  
*Celeste Shelton Ohlsen and David C. Whitcomb*
- 46 Epidemiology and Pathophysiology of Tropical Chronic Pancreatitis** 383  
*Shailesh V. Shrikhande and Savio G. Barreto*
- 47 CFTR-Associated Pancreatic Disease** 390  
*Chee Y. Ooi and Aliye Uc*
- 48 Alcohol and Smoking in Chronic Pancreatitis** 396  
*Atsushi Masamune, Kazuhiro Kikuta, and Kiyoshi Kume*
- 49 Idiopathic and Rare Causes of Chronic Pancreatitis** 404  
*Morihisa Hirota and Toru Shimosegawa*
- 50 Early Chronic Pancreatitis** 412  
*Kazuhiro Kikuta and Atsushi Masamune*
- 51 Chronic Pancreatitis with Inflammatory Mass in the Pancreatic Head** 418  
*Ulrich F. Wellner, Kim C. Honselmann, and Tobias Keck*
- 52 Structural Complications: Strictures, Stones, Pseudocysts, and Vascular Complications** 424  
*Xiaodong Tian, Xiaochao Guo, and Yinmo Yang*
- 53 Nutritional Evaluation and Support: An Overview** 430  
*Sinead N. Duggan and Stephen J. O'Keefe*
- 54 Exocrine Pancreatic Insufficiency** 436  
*Chris E. Forsmark*
- 55 Bone Disease in Chronic Pancreatitis** 442  
*Sinead N. Duggan*
- 56 Diabetes from Exocrine Pancreatic Disease** 445  
*Nao Fujimori, Tetsuhide Ito, and Yoshihiro Ogawa*
- 57 Oxidative Stress and Antioxidants in Chronic Pancreatitis** 451  
*Soumya Jagannath Mahapatra and Pramod Kumar Garg*
- 58 Pain Mechanisms in Chronic Pancreatitis** 460  
*Pierluigi Di Sebastiano, Fabio Francesco di Mola, Tommaso Grottola, and Rossana Percario*
- 59 Pain Management in Chronic Pancreatitis** 467  
*Louise Kuhlmann, Søren S. Olesen, and Asbjørn M. Drewes*

- 60 Adjunctive Therapy in Chronic Pancreatitis 474**  
*Anna Evans Phillips*
- 61 Pancreatic Cancer Risks in Chronic Pancreatitis 480**  
*Patrick Maisonneuve and Albert B. Lowenfels*
- 62 Evidence of Endoscopic and Interventional Treatment of Chronic Pancreatitis and Pseudocysts 486**  
*Jörg Schirra, Simon Sirtl MD, Markus M. Lerch, and Julia Mayerle*
- 63 Major Pancreatic Resection for Chronic Pancreatitis: Indication, Goals, and Limitations 496**  
*Faik G. Uzunoglu and Jakob R. Izbicki*
- 64 Pancreatic Drainage Procedures: Techniques and Results 501**  
*Ulrich F. Wellner, Dirk Bausch, and Tobias Keck*
- 65 Duodenum-Preserving Pancreatic Head Resections for Chronic Pancreatitis: Techniques and Results 506**  
*Hans G. Beger, Bertram Poch, Yang Yinmo, and Waldemar Uhl*
- 66 Total Pancreatectomy with Islet Autotransplant 515**  
*Greg Beilman, Zachary Bergman, and Melena Bellin*
- 67 Minimally Invasive Surgical Management of Chronic Pancreatitis 523**  
*Gilbert Z. Murimwa, Herbert J. Zeh III, and Matthew R. Porembka*
- Section 5 Autoimmune Pancreatitis 533**
- 68 Epidemiology of Autoimmune Pancreatitis 535**  
*Terumi Kamisawa*
- 69 Molecular Immunology and Pathogenesis of Autoimmune Pancreatitis 540**  
*Yoh Zen*
- 70 Clinical Manifestation of Type 1 Autoimmune Pancreatitis 546**  
*Tooru Shimosegawa*
- 71 Clinical Manifestation of Type 2 Autoimmune Pancreatitis 554**  
*Nicolò de Pretis and Luca Frulloni*
- 72 Clinical Diagnostic Criteria for Autoimmune Pancreatitis 561**  
*Tooru Shimosegawa*
- 73 Laboratory Diagnosis of Autoimmune Pancreatitis 568**  
*J-Matthias Löhr and Miroslav Vujanovic*
- 74 What is the Evidence Measuring Immune Markers 573**  
*Shigeyuki Kawa, Takayuki Watanabe, and Norihiro Ashihara*
- 75 Autoimmune Pancreatitis and IgG4-Related Disease 579**  
*Kazuichi Okazaki, Tsukasa Ikeura, and Kazushige Uchida*
- 76 Imaging Diagnosis of Autoimmune Pancreatitis 595**  
*Kazuichi Okazaki, Makoto Takaoka, Tsukasa Ikeura, and Kazushige Uchida*

- 77 Medical Management of Autoimmune Pancreatitis 600**  
*Shounak Majumder and Suresh T. Chari*
- 78 Management of Intractable Autoimmune Pancreatitis 605**  
*Shounak Majumder and Suresh T. Chari*
- 79 Long-Term Outcome After Treatment of Autoimmune Pancreatitis 609**  
*Luca Frulloni and Nicolò de Pretis*
- Section 6 Neoplastic Tumors of the Exocrine Tissue: Benign Cystic Neoplasms of the Pancreas 615**
- 80 Epidemiology of Cystic Neoplasms of the Pancreas 617**  
*Shounak Majumder and Suresh T. Chari*
- 81 Histologic Classification and Staging of Cystic Neoplasms 623**  
*Noriyoshi Fukushima and Giuseppe Zamboni*
- 82 Molecular Mechanisms of Cystic Neoplasia- 630**  
*Nickolas Papadopoulos and Ralph H. Hruban*
- 83 Clinical Presentation of Pancreatic Cystic Neoplasms 638**  
*Masao Tanaka*
- 84 Evaluation of Cystic Lesions Using EUS, MRI, and CT 642**  
*Anne Marie Lennon and Atif Zaheer*
- 85 Cytologic Evaluation of Cystic Neoplasms: The Role of Liquid Biopsy 652**  
*Abdulwahab Ewaz and Michelle D. Reid*
- 86 Natural History of Cystic Neoplasms: IPMN, MCN, SCN, and SPN 666**  
*Rosa Klotz, Thilo Hackert, and Markus W. Büchler*
- 87 Surveillance or Surgical Treatment in Asymptomatic Cystic Neoplasm 674**  
*Klaus Sahora and Carlos Fernández-del Castillo*
- 88 Artificial Intelligence in the Detection and Surveillance of Cystic Neoplasms 680**  
*Linda C. Chu and Elliot K. Fishman*
- 89 Oncologic Resection of IPMN and MCN: Open Approach—Results 688**  
*Marco Del Chiaro, Michael J. Kirsch, and Richard D. Schulick*
- 90 Surgical Treatment of Cystic Neoplasms: Laparoscopic and Robotic Approach—Results 693**  
*Benedict Kinny-Köster, Christopher L. Wolfgang, Markus W. Büchler, and Thilo Hackert*
- 91 Robotic-assisted Resection of Cystic Neoplasms 700**  
*Kimberly Kopecky and Jin He*
- 92 Duodenum-preserving Pancreatic Head Resection for Cystic Neoplasms of the Pancreatic Head: Indications and Limitations 709**  
*Hans G. Beger and Bertram Poch*
- 93 Pancreatic Middle Segment Resection of Cystic Neoplasms: Indications and Limitations 715**  
*Calogero Iacono and Mario De Bellis*

- 94 Tumor Enucleation for Cystic Neoplasms of the Pancreas: Indications and Limitations** 723  
*Rachel C. Kim, C. Max Schmidt, and Henry A. Pitt*
- 95 Duodenum-preserving Pancreatic Head Resection and Local Extirpation of SPTP in Children and Adolescents: Indications and long-term results** 732  
*Jiri Snajdauf, Michal Rygl, Barbora Kucerova, and Natalia Newland*
- 96 Management of Recurrence of Cystic Neoplasms** 737  
*Anna Nießen, Christopher L. Wolfgang, Thilo Hackert, and Markus W. Büchler*
- 97 Long-term Outcome after Observation and Surgical Treatment of Cystic Neoplasms: What is the Evidence?** 744  
*Roberto Salvia, Giovanni Marchegiani, Giampaolo Perri, and Claudio Bassi*
- Section 7 Neoplastic Tumors of the Endocrine Pancreas: Neuroendocrine Tumors of the Pancreas** 751
- 98 Epidemiology and Classification of Neuroendocrine Tumors of the Pancreas** 753  
*J.J. Mukherjee, K.O. Lee, and Gregory Kaltsas*
- 99 Pathology of Neuroendocrine Neoplasms** 763  
*Atsuko Kasajima and Hironobu Sasano*
- 100 Molecular Genetics of Neuroendocrine Tumors** 771  
*Nickolas Papadopoulos and Ralph H. Hruban*
- 101 What is the Origin of Pancreatic Endocrine Tumors?** 781  
*Aurel Perren, Iacovos P. Michael, and Ilaria Marinoni*
- 102 Clinical Manifestation of Endocrine Tumors of the Pancreas** 791  
*Tetsuhide Ito, Keijiro Ueda, Nao Fujimori, and Robert T. Jensen*
- 103 Evidence of Hormonal, Laboratory, Biochemical, and Instrumental Diagnostics of Neuroendocrine Tumors of the Pancreas** 799  
*K.O. Lee, Gregory Kaltsas, and J.J. Mukherjee*
- 104 Pancreatic Neuroendocrine Tumors in Multiple Neoplasia Syndromes** 808  
*Anja Rinke and Thomas Matthias Gress*
- 105 Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Diagnosis and Management Principles** 815  
*Takao Ohtsuka, Yuto Hozaka, and Hiroshi Kurahara*
- 106 Medical and Nucleotide Treatment of Neuroendocrine Tumors of the Pancreas** 820  
*Marina Tsoli and Gregory Kaltsas*
- 107 Interventional Radiology in the Treatment of Pancreatic Neuroendocrine Tumors** 829  
*Tetsuya Idichi, Hiroshi Kurahara, and Takao Ohtsuka*
- 108 Enucleation of Benign, Neuroendocrine Tumors of the Pancreas** 833  
*Frank Weber, Andreas Machens, and Henning Dralle*
- 109 Duodenum-Preserving Pancreatic Head Resection or Local Extirpation of Neuroendocrine Tumors of the Pancreas Larger than 2 cm** 841  
*Takashi Hatori*

- 110 **Individualized Surgery for Nonfunctional Pancreatic Neuroendocrine Tumors (NF-pNET) <2 cm: Indication, Surgical Principles, and Long-term Outcome** 849  
*Charles de Ponthaud, Julien de Martino, and Sébastien Gaujoux*
- 111 **Surgical Treatment of Endocrine Tumors: Major Oncologic Resection** 857  
*Frank Weber, Andreas Machens, and Henning Dralle*
- 112 **The Management of Insulinoma** 865  
*Keiji Ueda, Nao Fujimori, Robert T. Jensen, and Tetsuhide Ito*
- 113 **Evidence of Medical and Surgical Treatment of Gastrinoma** 872  
*Ryuichiro Doi*
- 114 **Rare Neuroendocrine Tumors of Pancreas: Management and Evidence of Surgical Treatment** 876  
*Ryuichiro Doi*
- 115 **Treatment of Neuroendocrine Neoplasia of the Pancreas and Biliary Tract** 882  
*Andrea Frilling, Ashley K. Clift, and Vito Cicinnati*
- 116 **Survival after Treatment of Endocrine Tumors** 891  
*Zhe Cao and Taiping Zhang*
- Section 8 Neoplastic Tumors of Exocrine Tissue: Pancreatic Cancer** 897
- 117 **Epidemiology of Pancreatic Cancer** 899  
*Evelina Mocci and Alison P. Klein*
- 118 **Smoking, a Risk for Pancreatic Cancer: Experimental and Clinical Data** 905  
*Uwe A. Wittel, Bradley R. Hall, and Surinder K. Batra*
- 119 **Molecular Understanding of the Development of Ductal Pancreatic Cancer** 912  
*Jae W. Lee, Ralph H. Hruban, and Laura D. Wood*
- 120 **From Tissue Turnover to the Cell of Origin of Pancreatic Cancer: An Updated View** 921  
*Bo Kong, Eva Thoma, and Christoph W. Michalski*
- 121 **Microbiome of Pancreatic Cancer: Involvement in Cancer Development and Chemo-/Immunotherapy** 928  
*Xianjun Yu*
- 122 **Molecular Subtypes and Clinical Applications** 934  
*Maarten F. Bijlsma and Peter Bailey*
- 123 **Tumor Microenvironment: Immune Cells and Immunosuppressive Functions of Carcinoma-associated Fibroblasts and Macrophages** 942  
*Tony Pang, Zhihong Xu, Chamini Perera, and Minoti V. Apte*
- 124 **Familial Pancreatic Cancer** 951  
*Alison P. Klein*
- 125 **Pathology of Exocrine Pancreatic Tumors** 957  
*Meredith E. Pittman and Ralph H. Hruban*

- 126 Pancreatic Cancer: Precancerous Lesions** 969  
*Michael J. Pflüger, Michaël Noë, and Lodewijk A.A. Brosens*
- 127 Clinical History and Risk Factors of Pancreatic Cancer** 982  
*Norbert Hüser, Volker Aßfalg, and Helmut Friess*
- 128 The Role of Endoscopic Ultrasonography in the Diagnosis and Differential Diagnosis of Neoplastic Lesions** 989  
*Yoshiki Hirooka, Senju Hashimoto, and Eizaburo Ohno*
- 129 Radiologic Diagnosis of Pancreatic Cancer: CT, MRI** 997  
*Hannah S. Recht and Elliot K. Fishman*
- 130 Screening of Hereditary Pancreatic Cancer** 1012  
*Michael Goggins*
- 131 The Role of PET in Diagnosis of Pancreatic Cancer and Cancer Recurrence** 1021  
*Norbert Hüser, Volker Aßfalg, Isabel Rauscher, and Helmut Friess*
- 132 Tumor Markers in Pancreatic Malignancies** 1028  
*Shin Hamada and Atsushi Masamune*
- 133 The Role of Laparoscopy and Peritoneal Cytology in the Management of Pancreatic Cancer** 1033  
*Yosuke Kasai, Kyoichi Takaori, and Etsuro Hatano*
- 134 Clinical Assessment and Staging of Advanced Pancreatic Cancer** 1037  
*James M. Lindberg, Giles F. Whalen, and Jennifer LaFemina*
- 135 Pancreatic Cancer: Indications for Resection** 1047  
*Akimasa Nakao and Suguru Yamada*
- 136 Pancreatoduodenectomy for Pancreatic Cancer: Short- and Long-term Outcome after Kausch-Whipple and Pylorus-preserving Pancreatoduodenectomy** 1055  
*Benedict Kinny-Köster, John L. Cameron, and Jin He*
- 137 Left Pancreatectomy for Body and Tail Cancer** 1063  
*Jony van Hilst, Mohammad Abu Hilal, and Marc G Besselink*
- 138 Total Pancreatectomy: Indications and Limitations** 1071  
*Seiko Hirono and Hiroki Yamaue*
- 139 Minimally Invasive Resection for Pancreatic Cancer** 1078  
*Patricio M. Polanco, Imad Radi, and Herbert J. Zeh III*
- 140 Robotic Resection for Pancreatic Cancer** 1093  
*Renyi Qin*
- 141 Extended Radical Surgery for Pancreatic Cancer** 1099  
*Thilo Hackert, Anna Nießen, and Markus W. Büchler*
- 142 Palliative Pancreatic Resection: Is It Justified?** 1108  
*Kira C. Steinkraus, Max Heckler, Christoph W. Michalski, and Felix J. Hüttner*
- 143 Outcome of Patients after R0 Resection for Locally Advanced Pancreatic Cancer Combined with Hepatic Metastasectomy: Indications and Limitations** 1113  
*Tingbo Liang*



- 144 Bypass Surgery for Advanced Pancreatic Cancer 1117**  
*Eva Thoma, Thilo Hackert, Christoph W. Michalski, and Felix J. Hüttner*
- 145 Endoscopic and Interventional Palliation of Pancreatic Cancer 1122**  
*Kazumasa Nagai and Takao Itoi*
- 146 Neoadjuvant Treatment of Pancreatic Cancer: Evidence for Treatment Effect 1131**  
*Robert A. Wolff*
- 147 Locally Advanced Pancreatic Cancer: Does the Addition of Stereotactic Body Radiation Therapy to Neoadjuvant Chemotherapy Lead to a Significant Survival Improvement after R0 Resection? 1141**  
*Marco Del Chiaro, Michael J. Kirsch, and Richard D. Schulick*
- 148 Adjuvant Chemotherapy in Pancreatic Cancer: First Line and Second Line Treatment—Benefits of Survival 1143**  
*Kulbir Mann, Robert P. Jones, Paula Ghaneh, and John P. Neoptolemos*
- 149 Role of Radiation Therapy for Pancreatic Cancer 1153**  
*Baho U. Sidiqi, Abhinav V. Reddy, Joseph M. Herman, and Amol K. Narang*
- 150 Immunotherapy for Pancreatic Cancer: Checkpoint Blockade and Vaccine Therapy 1164**  
*Arsen Osipov, Adrian G. Murphy, and Lei Zheng*
- 151 Targeted Therapies for Pancreatic Cancer 1180**  
*Anirban Maitra*
- 152 Precision Cancer Medicine 1188**  
*Grace Oh, Surajit Dhara, and Diane Simeone*
- 153 Palliative Chemotherapy for Advanced Pancreatic Cancer: Treatment Modalities, Side-effects, and Benefits of Survival 1196**  
*Christoph Springfield and Thomas Seufferlein*
- 154 Management of Pain in Pancreatic Cancer 1201**  
*Annie W. Hsu, Ayodeji Omosule, and Michael Erdek*
- 155 Management of Cancer Recurrence 1208**  
*Oliver Strobel, Martin Loos, and Markus W. Büchler*
- 156 Survival and Late Morbidity after Resection of Pancreatic Cancer 1218**  
*Avinoam Nevler and Charles J. Yeo*
- Section 9 Periampullary Cancers and Tumors Other Than Pancreatic Cancer 1233**
- 157 Periampullary Tumors: Clinical Presentation and Diagnostic Strategies 1235**  
*Jon M. Harrison and Keith D. Lillemoe*
- 158 Histology and Genetics of Cancer of the Papilla, Distal Common Bile Duct, and Duodenum 1242**  
*Yue Xue, Michelle D. Reid, and Volkan Adsay*
- 159 Adenoma and Adenocarcinoma of the Ampulla of Vater: Diagnosis and Management 1254**  
*Sahin Coban, Omer Basar, and William R. Brugge*

- 160 Endoscopic Treatment of Adenomas of the Ampulla of Vater: Techniques, Results, Benefits, and Limitations 1264**  
*Natsuyo Yamamoto and Hiroyuki Isayama*
- 161 Surgical Treatment of Papillary and Ampullary Tumors: Management and Long-term Results 1272**  
*Norbert Hüser, Volker Aßfalg, and Helmut Friess*
- 162 Surgical Treatment of Duodenal Cancer 1281**  
*Fuyuhiko Motoi*
- 163 Surgical Treatment of Distal Cholangiocarcinoma 1284**  
*Shunsuke Onoe, Yukihiro Yokoyama, and Tomoki Ebata*
- 164 Adjuvant and Palliative Chemotherapy of Periapillary Cancers 1291**  
*Arachchige D.N.R. Ponweera, Paula Ghaneh, and John P. Neoptolemos*
- 165 Long-term Survival After Resection of Periapillary Cancer 1299**  
*Hideyuki Yoshitomi, Masayuki Ohtsuka, and Masaru Miyazaki*
- Section 10 Transplantation of the Pancreas 1309**
- 166 Transplantation of Pancreatic Islets 1311**  
*Joseph Sushil Rao, Melena D. Bellin, and Bernhard J. Hering*
- 167 Transplantation of the Pancreas 1323**  
*Rainer W.G. Gruessner and Angelika C. Gruessner*
- Index 1333**

## About the Companion Website

This book is accompanied by a companion website.

[www.wiley.com/go/beger/thepancreas4](http://www.wiley.com/go/beger/thepancreas4)



This website includes:

- PowerPoints of all figures from the book for downloading
- List of Contributors
- List of Abbreviations



## Section 1

### Anatomy of the Pancreas



## 1

## Development of the Pancreas and Related Structures

Brian Lewis and Junhao Mao

Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA

### Anatomy of the Pancreas


The pancreas is a unique exocrine and endocrine organ located in the retroperitoneal region of the upper abdominal cavity. In humans, when fully formed, the organ has a distinct head, body, and tail, with the head of the pancreas contacting the duodenal region of the intestines (the main pancreatic duct drains into the duodenum) and the tail of the pancreas abutting the spleen. The greatest mass of the organ is present in the head, which is composed of tissue derived from two independent anlagen (see later). In other mammals, such as dogs and mice, the organ has a far less distinct structure and is identified as an amorphous pink tissue adjacent to the mesentery that runs along the upper intestinal wall.

The cells of the pancreas are arranged into distinct lobules composed primarily of the digestive enzyme-producing cells of the exocrine pancreas, which are arranged into acini (so-called acinar cells), the ductal structures that conduct these digestive enzymes to the intestines, and distinct clusters of endocrine cells, the islets of Langerhans, that secrete hormones and function to regulate glucose uptake and release and serum glucose levels. There are five recognized cell types within the islets, the  $\alpha$ ,  $\beta$ ,  $\delta$ ,  $\epsilon$ , and PP cells, which produce the hormones glucagon, insulin, somatostatin, ghrelin, and pancreatic polypeptide, respectively. The majority of the pancreatic tissue mass (more than 90–95%) is present within the exocrine compartment of the organ, with the islets of Langerhans, scattered throughout the tissue. The pancreas also has connective tissue, derived from the embryonic mesenchyme, which forms the septa that separate the many lobules of the organ. Mesenchyme-derived stromal cells are also present in the interlobular regions surrounding the pancreatic ducts, blood vessels,

and nerves. In the following sections, we explore how these disparate cell types come together to form the pancreas.

### Organogenesis in the Region of the Pancreas

Around day 14, the embryonic bilaminar germ disk is composed of a layer of epiblast and a layer of hypoblast. At this time, a faint groove appears along the longitudinal midline of the germ disk that develops into a structure called the primitive streak [1]. Around day 15, epiblast cells near the primitive streak undergo a morphologic change and migrate through the primitive streak into the space between the epiblast and hypoblast in a process known as gastrulation (Fig. 1.1). Some of the ingressing epiblast cells invade the hypoblast, which is eventually replaced by a new layer of epiblast-derived cells known as the definitive endoderm. Additional migrating epiblast cells occupy the space between the epiblast and the definitive endoderm to form a third layer of cells called the intraembryonic mesoderm (Fig. 1.1). As cells of the germinal disk migrate anteriorly to form a head process and lateral regions roll underneath to form an approximately cylindrical body shape, the endoderm is rolled into a tube that projects into the developing head region of the embryo surrounded by the mesoderm layer. This is the primitive digestive tube. The pancreas is specified by two separate outgrowths that arise on the dorsal and ventral surfaces of the primitive digestive tube. The epithelial cells of the pancreas originate from the interior lining of the primitive gut tube, which consists of a single layer of endoderm. A layer of mesenchyme, from which the muscle and



**Figure 1.1** Germ disks sectioned through the region of the primitive streak, showing gastrulation. (a) On days 14 and 15, the ingressing epiblast cells replace the hypoblast to form the definitive endoderm. (b) The epiblast that ingresses on day 16 migrates between the endoderm and epiblast layers to form the intraembryonic mesoderm. Source: Larsen 2001 [1]. Reproduced with permission of Elsevier.

connective tissue of the gastrointestinal organs are derived, surrounds the endoderm.

The anterior regions of the endoderm form the foregut; regions posterior to the foregut form the midgut and hindgut. The most anterior regions of the foregut give rise to the esophagus and stomach. Just posterior to the foregut, the endoderm is continuous with the yolk sac, which extends outside the embryo, in a region known as the anterior intestinal portal. Endodermally derived cells close to the anterior intestinal portal specify the pancreas. The duodenum and liver are also specified by foregut endoderm in this region.


Thus, many gastrointestinal tissues are specified at the same time from a fairly restricted region of the gut endoderm. How are each of these organs specified in the appropriate anatomic location, and how do they differentiate properly into mature functional organs? The epithelial organs of the developing embryo originate as buds from the endoderm as the appropriate temporal and spatial cues are received. Thus, proper initiation and location of endodermally derived organs are regulated by the activation status of important signal transduction pathways involved in animal development, including the hedgehog, Notch, and fibroblast growth factor (FGF) signaling pathways.

### Early Pancreatic Development

During the fourth week of gestation, two buds appear on the dorsal and ventral sides of the foregut near the anterior intestinal portal. These epithelial buds indicate the specification of the pancreas. These buds initially grow

and differentiate independently, but later fuse to form a single organ. The anlage on the dorsal side, the dorsal pancreatic bud, appears first and gives rise to the dorsal pancreas. The cells of the dorsal pancreas will give rise to the head, body, and tail of the mature pancreas. The second pancreatic anlage appears shortly after the appearance of the dorsal pancreatic bud. This bud, which appears on the ventral side of the gut tube, is appropriately called the ventral pancreatic bud and develops into the ventral pancreas, which forms part of the head of the pancreas. Both pancreatic buds develop simultaneously, and the proliferating epithelial cells grow as projections into the surrounding mesenchymal tissue. During this time, the development of the intestines, and importantly the duodenum, continues. Rotation and asymmetric growth of the duodenum move the originally ventral part to a dorsal location, carrying with it the ventral pancreas and the primordial common bile duct. As the duodenum begins to rotate into its appropriate anatomic location, the ventral pancreas also rotates around the gut tube such that the ventral and dorsal pancreata lie adjacent to each other. These pancreatic rudiments then fuse to form a single organ. While both developing pancreatic buds independently form pancreatic ducts, the lumens of which are continuous with the lumen of the primitive gut, after they fuse their primary ducts anastomose to form the main pancreatic duct (Fig. 1.2). The region of the primary duct of the ventral pancreas proximal to the duodenum fuses with the primary duct of the dorsal pancreas and becomes the primary drainage into the duodenum, entering the duodenum immediately adjacent to the common bile duct. The proximal region of the primary duct of the dorsal pancreas sometimes





**Figure 1.2** Contributions of the dorsal and ventral pancreas to the definitive organ. The ventral pancreas becomes most of the head. The dorsal pancreas becomes the remainder of the head, plus the body and tail. The duct of the dorsal pancreas contributes a large part of the main pancreatic duct plus the accessory duct. The duct of the ventral pancreas becomes the part of the main duct nearest the duodenum.

remains as an accessory drainage but often regresses. The ducts sometimes fail to fuse, in which event two independent duct systems drain into the duodenum.

### Signaling Governing Early Pancreatic Development

Early pancreatic development and establishing pancreatic identity are governed by the interplay between several critical transcription factors and intercellular signaling pathways. PDX1 and PTF1A are among the earliest transcription factors expressed in the pancreatic progenitor populations, and their functions are critical for pancreatic development [2–5]. In mice, PDX1 expression is first detected in the primitive gut tube at embryonic day 8.5 (E8.5), which corresponds to ~25–27 days in humans. PDX1 expression demarcates the prospective pancreatic domain, which is then followed by PTF1A expression in pancreatic endoderm at E9.5 [5–7]. Mice lacking either transcription factor display pancreatic agenesis [2,3,5,8].

In addition to the transcription factors, several key intercellular signaling pathways between gut endoderm and mesenchyme, including the hedgehog, FGF, Notch and Hippo pathways, play important roles in establishing the pancreatic identity and controlling the expression of these transcription factors. Research studies have shown that sonic hedgehog (SHH), the ligand of the hedgehog pathway, is excluded from the prospective pancreatic region, but is present in the region of foregut that becomes the duodenum, and ectopic expression of SHH

in the pancreas induces an intestinal fate, suggesting that SHH signaling may specify a duodenal versus pancreatic fate in the posterior foregut [9,10]. Another well-understood pathway mediating the mesenchymal–epithelial interaction is the FGF signaling pathway, in particular the FGF10–FGFR2 ligand–receptor pair. During early pancreatic development, FGF10 is highly expressed in the primitive mesenchyme, whereas its receptor FGFR2 is present in the pancreatic epithelium [11]. Mouse genetic experiments demonstrated that FGF10 provides the pro-proliferative signal to promote the expansion of the progenitor pool in the pancreatic epithelium [11]. In addition, FGF10 signaling from the mesenchymal cells is critical for maintaining the epithelial expression of SOX9 [12]. SOX9 is another transcription factor critical for early pancreatic development, and it exerts its function in part by controlling the expression of the FGF10 receptor FGFR2 [12,13]. Together, the complex regulatory loop between these signaling pathways and transcription factors in the epithelium and mesenchyme coordinates early organ growth and the establishment and maintenance of pancreatic identity.

### Differentiation of Pancreas Cell Types

The acinar, ductal, and endocrine cells of the pancreas are all produced through the proliferation and differentiation of the epithelial cells of both pancreas primordia. The cells appear homogeneous during the early stages of development as they proliferate and grow into the surrounding mesenchyme as finger-like projections. The epithelial cells form undifferentiated tubules that branch and anastomose as they penetrate into the mesenchyme to generate a tubular network, which resembles an immature (and nonfunctional) duct system. The acinar cells appear as clusters of cells at the ends of branches of this tubular network. The endocrine cells appear as cells that delaminate from the tubular epithelium and reaggregate in isolated clusters embedded within the developing parenchyma. The existing cells within these small isolated endocrine clusters proliferate, and these clusters therefore expand to form the islets.

Apparent differentiation of pancreas epithelial cells into endocrine cells can be identified beginning at 12 weeks of gestation with the detection of endocrine granules. Most of the endocrine differentiated cells identified at this time express glucagon and are therefore believed to be  $\alpha$  cells. Importantly, lineage-tracing experiments performed in mice demonstrated that these early  $\alpha$  cells do not act as endocrine progenitors, as  $\beta$  cells, the predominant cell type in the mature islet, are derived from glucagon-negative cells [14]. Differentiation of

acinar cells is detected at approximately 16 weeks, as identified by the appearance of zymogen granules. Interestingly, not all enzymes are elaborated at once—detection of trypsinogen does not occur until approximately 22 weeks. The digestive enzyme-positive cells arise as clusters from the undifferentiated tubules, the expansion of which is rapid such that the acinar cells become the dominant population within the organ. Although they are not yet mature acinar cells, the cells in the acinar clusters display some of their hallmark features, including basolaterally located nuclei. As differentiation continues, the cells become arranged in recognized acini and defined lobules surrounded by connective tissue. The ductal system arises after maturation of the immature tubular network. The specific morphologic changes that accompany this change are unclear, although some work suggests that Wnt signaling is involved in this transition [15].

### **Transcriptional Mechanisms Underlying Pancreatic Cell Fate Decision**

Much information about pancreatic cell fate determination and cell type differentiation has been obtained from studies in animal models. Elegant genetic and cell-based experiments in mice have identified a gene regulatory network controlled by many transcription factors to specify different cell lineages in the developing pancreas.

#### **Development of the Endocrine Lineage**

Endocrine cell specification begins with the expression of NGN3, a bHLH (basic helix–loop–helix) transcription factor, in a subset of progenitor cells within the trunk region of the pancreatic bud [16–18]. The NGN3-expressing cells eventually give rise to all endocrine cell types: insulin-producing  $\beta$  cells, glucagon-producing  $\alpha$  cells, somatostatin-producing  $\delta$  cells, ghrelin-producing  $\epsilon$  cells, and pancreatic polypeptide-producing PP cells [16–18]. NGN3 initiates endocrine lineage specification by inducing the expression of downstream transcription factors, including NeuroD, NKX2.2, PAX4, and ARX. Among them, NKX2.2, NeuroD, and PAX4 play key roles in the specification of  $\beta$  cells [19–21]. Mutant mice lacking any of these transcription factors display a phenotype of dramatic or total loss of  $\beta$  cells [19–21]. Further studies revealed that the opposing actions of PAX4 and ARX determine the fate choice between  $\alpha$  and  $\beta$  cells. During endocrine differentiation, loss of ARX leads to a complete loss of  $\alpha$  cells, but a concomitant increase in  $\beta$  and  $\delta$  cells [22], whereas loss of PAX4 results

in an opposite phenotype with loss of  $\beta$  and  $\delta$  cells and expansion of  $\alpha$  cells [20,22]. It is believed that this effect on cell fate choice is mediated by the reciprocal transcriptional repression between these factors.

#### **Differentiation of Acinar Cells**

Pancreatic acinar cells are primarily derived from precursor cells in the tip region, and their differentiation is coordinated by the transcription factor PTF1A, a master regulator of pancreatic development. Prior to exocrine differentiation, PTF1A forms a complex with the bHLH transcription factor RBP-Jk, and is required for activation of RBP-Jl, an acinar-specific paralog of RBP-Jk [23,24]. The more active RBP-Jl then replaces RBP-Jk to form the complex with PTF1A, thereby directly inducing the expression of many acinar-specific genes, including secretory peptides and digestive enzymes [23,24]. Interestingly, PDX1, another factor important for early pancreatic morphogenesis, is also involved in acinar differentiation. Although not essential for initial acinar specification, it appears that PDX1 is required for terminal differentiation of acinar cells [25]. Other transcription factors, such as NR5A2 and MIST1, are also required for acinar differentiation and homeostasis, likely through the interaction with the PTF1A/RBP-Jk/l complex [26,27].

#### **Ductal Cell Differentiation and Lineage Plasticity**

During development, NGN3-positive cells in the trunk region of the pancreatic bud give rise to endocrine cells, whereas NGN3-negative trunk epithelial cells contribute to the ductal system [28,29]. A number of transcription factors, such as SOX9, PROX1, HES1, and HNF6, are expressed in the ductal lineage and play various roles in ductal differentiation, including primary cilia formation in the ductal epithelial cells [30–33]. The Notch signaling pathway is the main determinant for promoting and maintaining the ductal cell identity [31]. Although the three lineages (endocrine, exocrine, and ductal) are specified during early development, the adult pancreatic cells from different lineages show remarkable plasticity and trans-differentiation capacity in pancreatic injury, pancreatitis, and tumorigenesis, which may shed light on the mechanisms underlying these pancreatic pathologies.

#### **Development and Disease**

Molecules important in the development of the pancreas are also causally associated with pancreatic disorders. Several of the signaling pathways involved in normal

pancreas development, such as the Notch, hedgehog, Hippo/YAP and Wnt signaling pathways, are commonly dysregulated in pancreatic ductal adenocarcinomas [34–40]. Aberrant activation of Wnt signaling drives the development of other pancreatic tumor types such as acinar carcinomas, pancreatoblastoma, and mucinous cystic neoplasms [41–43].

In diabetes, mutation of the transcription factor PDX1, which is important for pancreas specification and for proper  $\beta$ -cell maturation and function, is a cause of maturity-onset diabetes of the young (MODY) [44]. Other transcription factors that are critical for  $\beta$ -cell development (as determined by genetic studies in the mouse), such as hepatocyte nuclear factor 1 $\alpha$  (HNF1 $\alpha$ ), HNF1 $\beta$ , HNF4 $\alpha$ , and NeuroD, are all also mutated in additional MODY complementation groups [44]. More recently, scientists have utilized our growing understanding of normal

pancreas development to promote the differentiation of induced pluripotent stem cells into insulin-producing cells in a new potential therapeutic approach for diabetes [45–47].

Collectively, these findings illustrate the importance of key regulators of pancreas development and differentiation in pathologic disease states and how knowledge of normal pancreas development may drive new therapeutic strategies for pancreatic diseases.

## Acknowledgment

Work in the authors' laboratories is supported by grants from the National Institutes of Health. The authors apologize to colleagues for not citing much of the primary literature due to space constraints.

## References

- Larsen W. Human Embryology, 3rd edn. Philadelphia: Churchill Livingstone, 2001.
- Ahlgren U, Jonsson J, Edlund H. The morphogenesis of the pancreatic mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/PDX1-deficient mice. *Development* 1996;122(5):1409–1416.
- Offield MF, Jetton TL, Labosky PA et al. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. *Development* 1996;122(3):983–995.
- Krapp A, Knofler M, Ledermann B et al. The bHLH protein PTF1-p48 is essential for the formation of the exocrine and the correct spatial organization of the endocrine pancreas. *Genes Dev* 1998;12(23):3752–3763.
- Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald RJ, Wright CV. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. *Nat Genet* 2002;32(1):128–134.
- Guz Y, Montminy MR, Stein R et al. Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. *Development* 1995;121(1):11–18.
- Krapp A, Knofler M, Frutiger S, Hughes GJ, Hagenbuchle O, Wellauer PK. The p48 DNA-binding subunit of transcription factor PTF1 is a new exocrine pancreas-specific basic helix–loop–helix protein. *EMBO J* 1996;15(16):4317–4329.
- Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. *Nature* 1994;371(6498): 606–609.
- Hebrok M, Kim SK, Melton DA. Notochord repression of endodermal Sonic hedgehog permits pancreas development. *Genes Dev* 1998;12(11):1705–1713.
- Kawahira H, Ma NH, Tzanakakis ES, McMahon AP, Chuang PT, Hebrok M. Combined activities of hedgehog signaling inhibitors regulate pancreas development. *Development* 2003;130(20):4871–4879.
- Bhushan A, Itoh N, Kato S et al. Fgf10 is essential for maintaining the proliferative capacity of epithelial progenitor cells during early pancreatic organogenesis. *Development* 2001;128(24):5109–5117.
- Seymour PA, Shih HP, Patel NA et al. A Sox9/Fgf feed-forward loop maintains pancreatic organ identity. *Development* 2012;139(18):3363–3372.
- Seymour PA, Freude KK, Tran MN et al. SOX9 is required for maintenance of the pancreatic progenitor cell pool. *Proc Natl Acad Sci U S A* 2007;104(6):1865–1870.
- Murtaugh LC, Melton DA. Genes, signals, and lineages in pancreas development. *Annu Rev Cell Dev Biol* 2003;19:71–89.
- Heiser PW, Lau J, Takeito MM, Herrera PL, Hebrok M. Stabilization of  $\beta$ -catenin impacts pancreas growth. *Development* 2006;133(10):2023–2032.
- Gradwohl G, Dierich A, LeMeur M, Guillemot F. Neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. *Proc Natl Acad Sci U S A* 2000;97(4):1607–1611.
- Schwitzgebel VM, Scheel DW, Connors JR et al. Expression of neurogenin3 reveals an islet cell precursor population in the pancreas. *Development* 2000;127(16):3533–3542.
- Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. *Development* 2002;129(10):2447–2457.
- Naya FJ, Huang HP, Qiu Y et al. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine

- differentiation in BETA2/neuroD-deficient mice. *Genes Dev* 1997;11(18):2323–2334.
- 20 Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. *Nature* 1997;386(6623):399–402.
- 21 Sussel L, Kalamaras J, Hartigan-O'Connor DJ et al. Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. *Development* 1998;125(12):2213–2221.
- 22 Collombat P, Mansouri A, Hecksher-Sorensen J et al. Opposing actions of Arx and Pax4 in endocrine pancreas development. *Genes Dev* 2003;17(20):2591–2603.
- 23 Beres TM, Masui T, Swift GH, Shi L, Henke RM, MacDonald RJ. PTF1 is an organ-specific and Notch-independent basic helix–loop–helix complex containing the mammalian Suppressor of Hairless (RBP-J) or its paralogue, RBP-L. *Mol Cell Biol* 2006;26(1):117–130.
- 24 Masui T, Long Q, Beres TM, Magnuson MA, MacDonald RJ. Early pancreatic development requires the vertebrate Suppressor of Hairless (RBPJ) in the PTF1 bHLH complex. *Genes Dev* 2007;21(20):2629–2643.
- 25 Hale MA, Kagami H, Shi L et al. The homeodomain protein PDX1 is required at mid-pancreatic development for the formation of the exocrine pancreas. *Dev Biol* 2005;286(1):225–237.
- 26 Pin CL, Rukstalis JM, Johnson C, Konieczny SF. The bHLH transcription factor Mist1 is required to maintain exocrine pancreas cell organization and acinar cell identity. *J Cell Biol* 2001;155(4):519–530.
- 27 Holmstrom SR, Deering T, Swift GH et al. LRH-1 and PTF1-L coregulate an exocrine pancreas-specific transcriptional network for digestive function. *Genes Dev* 2011;25(16):1674–1679.
- 28 Wang S, Yan J, Anderson DA et al. Neurog3 gene dosage regulates allocation of endocrine and exocrine cell fates in the developing mouse pancreas. *Dev Biol* 2010;339(1):26–37.
- 29 Magenheimer J, Klein AM, Stanger BZ et al. Ngn3<sup>+</sup> endocrine progenitor cells control the fate and morphogenesis of pancreatic ductal epithelium. *Dev Biol* 2011;359(1):26–36.
- 30 Pierreux CE, Poll AV, Kemp CR et al. The transcription factor hepatocyte nuclear factor-6 controls the development of pancreatic ducts in the mouse. *Gastroenterology* 2006;130(2):532–541.
- 31 Shih HP, Kopp JL, Sandhu M et al. A Notch-dependent molecular circuitry initiates pancreatic endocrine and ductal cell differentiation. *Development* 2012;139(14):2488–2499.
- 32 Westmoreland JJ, Kilic G, Sartain C et al. Pancreas-specific deletion of Prox1 affects development and disrupts homeostasis of the exocrine pancreas. *Gastroenterology* 2012;142(4):999–1009.e6.
- 33 Delous M, Yin C, Shin D et al. Sox9b is a key regulator of pancreaticobiliary ductal system development. *PLoS Genet* 2012;8(6):e1002754.
- 34 Bailey P, Chang DK, Nones K et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016;531(7592):47–52.
- 35 Berman DM, Karhadkar SS, Maitra A et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. *Nature* 2003;425(6960):846–851.
- 36 Miyamoto Y, Maitra A, Ghosh B et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. *Cancer Cell* 2003;3(6):565–576.
- 37 Pasca di Magliano M, Biankin AV, Heiser PW et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. *PLoS ONE* 2007;2(11):e1155.
- 38 Thayer SP, Pasca di Magliano M, Heiser PW et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. *Nature* 2003;425(6960):851–856.
- 39 Mello SS, Valente LJ, Raj N et al. A p53 super-tumor suppressor reveals a tumor suppressive p53-Ptpn14-Yap axis in pancreatic cancer. *Cancer Cell* 2017;32(4):460–473.
- 40 Murakami S, Nemazanyy I, Whiteet SM et al. A Yap-Myc-Sox2-p53 regulatory network dictates metabolic homeostasis and differentiation in Kras-driven pancreatic ductal adenocarcinomas. *Dev Cell* 2019;51(1):113–128
- 41 Abraham SC, Wu TT, Hruban RH et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. *Am J Pathol* 2002;160(3):953–962.
- 42 Abraham SC, Wu TT, Klimstra DS et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. *Am J Pathol* 2001;159(5):1619–1627.
- 43 Sano M, Driscoll DR, De Jesus-Monge WE, Klimstra DS, Lewis BC. Activated Wnt signaling in stroma contributes to development of pancreatic mucinous cystic neoplasms. *Gastroenterology* 2014;146(1):257–267.
- 44 Edlund H. Pancreatic organogenesis—developmental mechanisms and implications for therapy. *Nat Rev Genet* 2002;3(7):524–532.
- 45 Velazco-Cruz L, Song J, Maxwell KG et al. Acquisition of dynamic function in human stem cell-derived  $\beta$  cells. *Stem Cell Reports* 2019;12(2):351–365.
- 46 Tremmel DM, Mitchell SA, Sackett SD, Odorico JS. Mimicking nature-made beta cells: recent advances towards stem cell-derived islets. *Curr Opin Organ Transplant* 2019;24(5):574–581.
- 47 Nair GG, Tzanakakis ES, Hebrok M. Emerging routes to the generation of functional  $\beta$ -cells for diabetes mellitus cell therapy. *Nat Rev Endocrinol* 2020;16(9):506–518.



## 2

## Anatomy, Histology, and Fine Structure of the Pancreas

Daniel S. Longnecker<sup>1</sup> and Elizabeth D. Thompson<sup>2</sup>

<sup>1</sup>Department of Pathology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA

<sup>2</sup>The Johns Hopkins University School of Medicine, Baltimore, MD, USA

### Introduction

This chapter reviews the anatomy, histology, and ultra-structure of the pancreas, including both the exocrine and endocrine portions. The exocrine pancreas produces and secretes digestive enzymes (e.g., trypsin, chymotrypsin, amylase, lipase) into the duodenum. The exocrine portion includes acinar cells and ducts with associated connective tissue, vessels, and nerves that comprise more than 95% of the pancreatic mass. The endocrine pancreas (islets of Langerhans) makes and secretes insulin, glucagon, somatostatin, and pancreatic polypeptide into the blood. The islets comprise 1–2% of pancreatic mass.

When the anatomic terms *anterior* and *posterior* are used in this chapter, they pertain to relationships in the human, standing erect. Similarly, *superior* and *inferior* mean toward the head and toward the feet, respectively. We will adopt the convention that *right* and *left* (unqualified) indicate the subject's right-hand and left-hand sides. However, when describing the location of structures within an image, *image right* and *image left* are used to denote relationships without reference to the subject's right or left side.

The organization and content of this chapter are based in part on a recent Pancreapedia chapter on pancreatic anatomy and histology [1].

### Gross Anatomy


The pancreas (meaning all flesh in Greek) lies in the posterior portion of the upper abdomen behind the stomach. It is largely retroperitoneal and is covered by peritoneum on the anterior surface of the head and body

and is surrounded by fat in this region. It is customary to refer to various portions of the pancreas as head, body, and tail. The head abuts the C-shaped second portion of the duodenum in the right upper quadrant of the abdomen. The tail emerges into the peritoneal cavity (covered by peritoneal serosa) and extends toward the hilum of the spleen in the left upper quadrant. The pancreas weighs about 100 g and is 14–25 cm long [2]. Figure 2.1 shows a human pancreas that has been dissected to isolate it from surrounding fat and adjacent organs and Fig. 2.2 is a drawing depicting a pancreas that has been dissected to reveal the pancreatic and common bile ducts.


The pancreas is intimately associated with several adjacent organs. Relationships of the pancreas to surrounding organs and structures are depicted in Figs 2.3, 2.4, 2.5, and 2.6. As noted above, as the duodenum exits the stomach it loops around the head of the pancreas. The tail of the pancreas lies near the hilum of the spleen. The body of the pancreas lies posterior to the pyloric region of the stomach.

The portion of the pancreas that lies anterior to the aorta is somewhat thinner in the anterior–posterior axis than the adjacent portions of the head and body of the pancreas. This region is designated as the neck and marks the junction of the head and body (Fig. 2.1b). The proximity of the neck of the pancreas to major blood vessels posteriorly, including the superior mesenteric artery, superior mesenteric-portal vein, inferior vena cava, and aorta, limits the options for a wide surgical margin during pancreatectomy (Fig. 2.5).

There is no anatomic landmark for the junction between the body and tail of the pancreas [3]. Hellman defined the tail as one-fourth of the pancreas from the tip of the tail toward the head [4] whereas Wittingen and



**Figure 2.1** This pancreas, from the autopsy of a 47-year-old woman, measures 22.5 cm in length and has been dissected free of most surrounding fat. (a) Anterior view with the head at image left. (b) Posterior view. A thin layer of fat (translucent yellow) covers a portion of the head at image right. Note the thin neck region just to the left of the head. (c) Cut surface of a transection through the head of the pancreas showing the lobular pancreatic parenchyma. *Source:* Dissection and photo by Catherine M. Nicka, MD.



**Figure 2.2** A pancreas dissected to reveal the pancreatic ducts and common bile duct as it traverses the head of the pancreas, ending as it joins the main pancreatic duct near the ampulla of Vater. Interlobular branches of the main duct are depicted but smaller ducts (intralobular ducts and ductules) are not. Eponyms identify the anatomist, embryologist, or physician who is credited with first describing a structure. Wirsung and Santorini were such scientists. *Source:* Drawing by Emily Weber.

Frey defined the junction between the body and tail as the point where the gland sharply narrows [5]. This point is difficult to define in some pancreases.

The common bile duct passes behind the upper portion of the head and then runs through the pancreas to join the main duct in the duodenal wall (Figs 2.2, 2.5, and 2.7b). The accessory pancreatic duct drains into the duodenum at the minor papilla in most humans, and the main pancreatic duct enters the duodenum at the major papilla (ampulla of Vater, Fig. 2.3). See Chapter 3 for discussion of pancreas divisum and other anomalies with possible clinical significance.

Typically, the bile duct and main pancreatic duct join into a “common channel” referring to the fused portion of the bile and pancreatic ducts proximal to its entry into the duodenal lumen. The common channel varies in length from a few millimeters to about 1 cm. A long common channel due to junction of the bile and pancreatic ducts proximal to the duodenal wall is regarded as an anomaly [6]. Less often, there is no common channel because the ducts open separately into the duodenum at the major